Literature DB >> 10534356

Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan.

H Y Hsu1, M H Chang, S H Liaw, Y H Ni, H L Chen.   

Abstract

Mutants of a determinant of hepatitis B surface antigen (HBsAg) identified in vaccinated children pose a potential threat to long-term success of vaccination programs. We examined the mutants of a determinant (residues 110-160) of HBsAg in hepatitis B virus (HBV) DNA-positive children identified during previous serosurveys in Taipei undertaken just before (1984), 5 years after (1989), and 10 years after (1994) universal vaccination began. In HBV DNA-positive children from 3 surveys, the prevalence of a determinant mutants increased from 8 of 103 (7.8%) in 1984 to 10 of 51(19.6%) in 1989 and 9 of 32 (28.1%) in 1994 and was higher in those fully-vaccinated than unvaccinated (12/33 vs. 15/153, P =. 0003). Most amino acid changes of the variants clustered in residues 125-129 and 140-149. In all 27 children with detectable mutants, the mean age of those vaccinated was younger than those unvaccinated (4. 8 +/- 3.8 vs. 7.9 +/- 2.3 yrs, P <.05); and mutations occurred in a region with greatest local hydrophilicity (residues 140-149) more frequently in those vaccinated than in those unvaccinated (10/12 vs. 6/15, P =.0253). More mutated residues and more mutations at neutralizing epitopes, such as N146, C147, T148, and C149, were found in the 1994 survey. Vaccinated children may contract variant infections through vertical or horizontal transmission. Universal vaccination has accelerated an accumulation of HBsAg a determinant mutants with amino acid changes critical for immune escape in vaccinated children who became carriers, suggesting that new vaccination strategies should be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534356     DOI: 10.1002/hep.510300511

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

1.  Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected argentine patient with anti-HBs antibodies.

Authors:  María L Cuestas; Verónica L Mathet; Vanesa Ruiz; María L Minassian; Cintia Rivero; Andrea Sala; Daniel Corach; Analía Alessio; Marcia Pozzati; Bernardo Frider; José R Oubiña
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Vaccination and the dynamics of immune evasion.

Authors:  Olivier Restif; Bryan T Grenfell
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

3.  The evolutionary epidemiology of vaccination.

Authors:  Sylvain Gandon; Troy Day
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

Review 4.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

5.  Quasispecies characters of hepatitis B virus in immunoprophylaxis failure infants.

Authors:  Xin Wang; Wanyan Deng; Keli Qian; Haijun Deng; Yong Huang; Zeng Tu; Ailong Huang; Quanxin Long
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-08       Impact factor: 3.267

6.  HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.

Authors:  Timothy Na Archampong; Ceejay L Boyce; Margaret Lartey; Kwamena W Sagoe; Adjoa Obo-Akwa; Ernest Kenu; Jason T Blackard; Awewura Kwara
Journal:  Antivir Ther       Date:  2016-05-11

7.  The effects of booster vaccination on hepatitis B vaccine in anti-HBs negative infants of HBsAg-positive mothers after primary vaccination.

Authors:  Hua Gu; Jun Yao; Wei Zhu; Huakun Lv; Suyun Cheng; Luoya Ling; Shichang Xia; Yongdi Chen
Journal:  Hum Vaccin Immunother       Date:  2013-02-19       Impact factor: 3.452

8.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

9.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

Review 10.  Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions.

Authors:  Mahmoud Reza Pourkarim; Samad Amini-Bavil-Olyaee; Fuat Kurbanov; Marc Van Ranst; Frank Tacke
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.